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Abstract 
The integrin antagonist cilengitide has been explored as an adjunct with anti-
angiogenic properties to standard of care temozolomide chemoradiotherapy 
(TMZ/RT→TMZ) in newly diagnosed glioblastoma. Preclinical data as well as 
anecdotal clinical observations indicate that anti-angiogenic treatment may result in 
altered patterns of tumor progression. Using a standardized approach, we analyzed 
patterns of progression on MRI in 21 patients enrolled onto a phase 2 trial of 
cilengitide added to TMZ/RT→TMZ in newly diagnosed glioblastoma. Thirty patients 
from the experimental treatment arm of the EORTC/NCIC pivotal TMZ trial served as 
a reference. MRIcro software was used to map location and extent of initial 
preoperative and recurrent tumors on MRI of both groups into the same stereotaxic 
space which were then analyzed using an automated tool of image analysis. Clinical 
and outcome data of the cilengitide-treated patients were similar to those of the 
EORTC NCIC trial except for a higher proportion of patients with a methylated O6-
methylguanyl-DNA-methyltransferase (MGMT) gene promoter. Analysis of 
recurrence pattern revealed neither a difference in the size of the recurrent tumor nor 
in the distance of the recurrences from the preoperative tumor location between 
groups. Overall frequencies of distant recurrences were 20% in the reference group 
and 19% (4/21 patients) in the cilengitide group. Compared with TMZ/RT→TMZ 
alone, the addition of cilengitide does not alter patterns of progression. This analysis 
does not support concerns that integrin antagonism by cilengitide may induce a more 
aggressive phenotype at progression, but also provides no evidence for an anti-
invasive activity of cilengitide in patients with newly diagnosed glioblastoma. 
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Introduction 
Most current efforts to improve the outcome for patients with newly diagnosed 
glioblastoma focus on the addition of anti-angiogenic agents to the standard of care 
of concomitant chemoradiotherapy with temozolomide (TMZ/RT→TMZ) [1]. The 
majority of pharmacological approaches focus on inhibition of the vascular 
endothelial growth factor (VEGF) pathway, but additional targets are being explored, 
notably integrins. Preclinical data obtained in rodent glioma models suggest that 
VEGF antagonism may induce a more infiltrative, disseminated phenotype of gliomas 
[2,3]. No such animal data are available for integrin antagonism.  
We have previously developed an analysis tool to explore whether comparable 
groups of patients differ in their patterns of progression. This tool was first used for 
analysis of the pivotal EORTC/NCIC TMZ trial; and allowed to falsify the hypothesis 
that the addition of TMZ to RT alters the pattern of progression of glioblastomas [4]. 
Similarly, using this tool we did not confirm the notion that bevacizumab therapy 
alters tumor biology to a more invasive phenotype [5]. In the present study, we asked 
whether patients treated with the integrin antagonist cilengitide would exhibit an 
altered pattern of progression. 
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Patients and methods 
We retrieved the matched pre- and post-operative MRI scans as well as the MRI 
scan documenting progression of patients enrolled into a single-arm phase 2 clinical 
trial of cilengitide plus TMZ/RT→TMZ in newly diagnosed glioblastoma [6]. Thirty 
patients from the experimental treatment arm of the EORTC/NCIC 26981/22981 
National Cancer Institute of Canada (NCIC) CE.3 trial served as a reference [1,4]. 
From these patients MRI scans at baseline and progression were available for a 
retrospective recurrence pattern analysis [4]. Patterns of progression were analyzed 
as described hereib; in brief, brain lesions were demonstrated by contrast-enhanced 
T1-weighted MRI sequences. The MR scans were oriented along the bicommissural 
plane. Mapping of lesions was performed blinded to the clinical features of the 
patients. The boundaries of the tumor location at baseline and at follow-up were 
delineated using MRIcro software [7] and mapped on the T1-template MRI from the 
Montreal Neurological Institute (www.bic.mni.mcgill.ca/cgi/icbm_view) that is 
distributed with MRIcro. Tumors were mapped for each individual patient, with 
separate tumor maps generated for both the baseline and recurrence scan. By 
transforming each individual brain and lesion into the same stereotaxic space, the 
procedure allowed us to superimpose lesions of different individuals to find regions of 
mutual involvement and conduct subtraction analysis. These techniques are well 
established in stroke research and have been applied to brain tumor patients before 
[4,5].  
Further, by using MRIcro, tumor volume and the location of the center-of-mass of the 
tumor for each individual were computed. The center-of-mass is the mean position 
for all tumor-affected voxels in each of the three spatial dimensions, resulting in a 
single cartesian coordinate (X,Y,Z position). In the case of a single spherical tumor, 
the center-of-mass thus will be located right in its center, while with, e.g. a U-shaped 
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configuration the center-of-mass may lie outside the tumor itself. Likewise this 
measure is influenced by satellites of the main tumor mass and thus sensitive to the 
development of satellites between baseline and recurrent images. 
For an additional case-by-case analysis a distant recurrence on T1 contrast-
enhanced (T1+c) sequences was defined as one of the following: a) qualitative 
assessment of well-defined recurrence centered outside a 2 cm margin around the 
outer border of the primary site or margin of the resection cavity or a shift of the 
center-of-mass by more than half of the diameter of the pretreatment tumor, b) new 
tumor satellites, c) new involvement of the contralateral hemisphere [4]. Only patients 
with progressive disease (PD) as the reason for failure of therapy were included. 
Analysis was done blinded to treatment in the reference or cilengitide group on 
contrast-enhanced T1-weighted images in the axial plane. The boundary of the tumor 
location at baseline and at follow-up was delineated using OsiriX software (Softonic, 
Stanford, CA, USA).  
A two-tailed t-test was conducted to determine if the two treatments influenced the 
size of recurrent tumors or the distance of the center-of-mass between the baseline 
and follow-up scan or both. A sample size of 20 per group would be sufficient to 
detect a 35% difference for the movement of the center-of-mass with a power of 70% 
that would be regarded clinically relevant.  
Median progression-free and overall survival for the cilengitide group were calculated 
by Kaplan-Meier survival analysis using SPSS software version 21 for Windows 
(IBM, Armonk, NY, USA). 
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Results 
For 21 representative patients (21/53, 40%) treated prospectively within the 
cilengitide added to standard TMZ/RTTMZ 010 pilot phase II protocol complete 
digitized imaging was available for review and analysis [6]. The reference group 
included all 30 patients with sufficient MRI information from the experimental arm of 
the EORTC 26981/22981 NCIC CE.3 trial, as previously reported [1,4]. Table 1 
summarizes characteristics of the patients, tumors and outcome of the two cohorts. 
Overall, patient characteristics appear comparable, with the exception of a higher 
proportion of patients with an unknown MGMT methylation status in the historical 
reference cohort (23% vs 14%). Patients in both groups did not differ with respect to 
extent of resection. The median time between imaging used for the baseline MRI 
scanning and first histological diagnosis was 0.2 months in both groups. The median 
time between baseline MRI and the MRI demonstrating recurrence was 7.3 months in 
the reference group and 9.0 months in the cilengitide group, comparable to the whole 
study cohort. 
To identify any preferential directions of tumor growth or of tumor shrinkage in either 
group, the tumor locations at baseline were subtracted from the superimposed tumor 
locations after treatment in each treatment group. For both treatment groups, we 
found no marked anatomical shift of tumor locations after treatment. The overlap 
frequencies after substraction did not exceed 35% of overlap at any location 
indicating that the anatomical differences between baseline and follow-up 
measurement were small and not directionally specific. 
Recurrent tumors volumes (measured in voxels on a per-patient basis) were 1.29-fold 
(±0.37) and 1.4-fold (±0.41) larger than the initial tumors in the reference group and  
in the cilengitide group, respectively (p=0.51) 
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For the center-of-mass measure, the distance between baseline and follow-up 
centroids was computed for each individual, providing a measure of excentricity or a 
large shift in location, e.g., when a new satellite tumor has developed. The movement 
of the center-of-mass between the baseline and follow-up scan in the reference 
cohort and the cilengitide cohort revealed no difference with a mean movement of 
12.03 mm (±0.39) for the reference group and 13.22 mm (±0.60) for the cilengitide 
treated patients (p=0.53). The case-by-case comparison suggested the same 
conclusion: the frequency of distant recurrences was 18% in the reference and 19% 
in the cilengitide group (Chi2=0.92, p=0.12). 
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Discussion 
 
The patterns of progression in glioblastoma have recently attracted a lot of interest, 
both because of preclinical data and clinical observations that suggested a specific 
change in the pattern of progression depending on treatment, i.e. radiotherapy, TMZ 
chemotherapy or novel anti-angiogenic treatments [8,9,3,10,2]. Using a previously 
established and standardized tool and radiological software we compared the pattern 
of progression of 21 patients who were prospectively treated with cilengitide in 
addition to standard TMZ/RTTMZ with 30 reference patients who received 
standard chemoradiotherapy alone in a previous clinical trial. In contrast to the initial 
hypothesis, we did not demonstrate a difference in invasion pattern or location of 
tumor recurrence (e.g. farther distance from the initial tumor location) for the patients 
having been treated with cilengitide. Interestingly, one patient from the cilengitide 
group who experienced a local recurrence intracranially was diagnosed with 
histologically proven pulmonary metastasis in the course of the disease. However, 
this case is exceptional and no further patients with systemic metastasis were 
described in this trial [6].  
Similar to cilengitide and despite strong preclinical evidence of development of a 
more aggressive phenotype and increased invasion after treatment with 
bevacizumab [2,3,10], a recent analysis of the imaging data of patients treated in the 
AVAGlio trial (bevacizumab added to TMZ/RT—TMZ) did not indicate a clinically 
relevant change in invasion pattern or tumor phenotype in bevacizumab-treated 
patients [11]. Yet, it is noteworthy that RTOG-0825, a similar trial, reported impaired 
quality of life and decreased scores on some tests of cognitive function in 
bevacizumab-treated patients, although no such data were reported by the AVAGlio 
investigators [11,12]. Careful comparison of both data sets including neuroimaging 
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will be necessary to better understand these conflicting data and a possible role of 
neuroimaging changes. 
While preclinical evidence suggested anti-invasive properties of TMZ, or potentially 
promotion of invasive escape mechanisms after irradiation, or after VEGF inhibition, 
systematic analyses of the pattern of treatment failure does not substantiate these 
findings in the clinical setting. Although all analyses were conducted on relatively 
small subsets of patients, the consistency of the finding raises questions to whether 
the preclinical models reflect the human situation adequately. 
This is the first analysis ever of a potential modulation of patterns of progression by 
the novel class of compounds of integrin inhibitors. The observation that no change 
in the patterns of progression in a cohort of cilengitide-treated patients compared to a 
cohort of patients from the experimental arm of the EORTC 26981/22981 NCIC CE.3 
was observed is reassuring. The major limitation of the present study is the small 
sample size and the uncertainty of its relevance in the future: preliminary results from 
the subsequently performed phase 3 trial, CENTRIC, indicate that the primary 
endpoint of prolonging overall survival was not reached [13]. Yet, our analysis serves 
as a baseline and reference for the future study of the role of modulation of integrins 
in the treatment of newly diagnosed glioblastoma. 
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Table Patient characteristics 
 
 MRI study cohort 
from [6] ( n=21) 
Complete study 
cohort from [6] 
(n=52) 
Reference cohort 
from EORTC 26981-
22981 NCIC CE3 
[1,4] (n=30) 
Patient characteristics No. of 
patients 
% No. of 
patients 
% No. of 
patients 
% 
Age, years 
         Median 
         Range 
 
53 
32-67 
 
57 
32-68 
 
56 
36-66 
Sex 
         Male 
         Female 
 
11 
10 
 
52 
48 
 
32 
20 
 
62 
38 
 
18 
12 
 
60 
40 
ECOG performance status 
         0 or 1 
         2 
 
20 
1 
 
95 
5 
 
48 
4 
 
92 
8 
KPS* 
90-100: n=18 
70-80: n=12 
 
60 
40 
Prior treatment 
          Corticosteroids 
          Debulking surgery 
              Complete resection 
              Partial resection 
         Biopsy 
 
19 
18 
9 
9 
3 
 
90 
86 
43 
43 
14 
 
43 
43 
23 
20 
9 
 
83 
83 
44 
39 
17 
 
23 
18 
n/a 
n/a 
12 
 
77 
60 
  
MGMT promoter status 
           Methylated 
           Unmethylated 
           Unknown 
 
9 
9 
3 
 
43 
43 
14 
 
23 
22 
7 
 
44 
42 
13 
 
10 
13 
7 
 
33 
43 
23 
Median PFS (months, 95% CI) 8.1 (6.4-9.8)  8.0 (6.0-10.7)  7.1 (5.8-8.2)  
Median OS (months, 95% CI) 15.7  
(11.2-20.1)* * 
 16.1 
(13.1-23.2) 
 14.4 (13.4-
16.8) 
 
 
*Eastern cooperative oncology group (ECOG) measure 0 = KPS 100; ECOG 1 = KPS 80 to 90; ECOG 2 = KPS 60 to 70, 
according to [13]. KPS: Karnofsky Performance Status. CI: confidence interval. n/a: information not available. PFS: progression-
free survival. OS: overall survival. 
**5 patients censored 
 
 
 
 
